-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17th, Kangzhe Pharmaceuticals' clinical application for a new drug was accepted by CDE.
is an oral hypoxic induction factor proline hydroxyase inhibitor (HIF-PHI) intended to treat anemia in patients with chronic kidney disease (CKD).
is developed by Cadila Healthcare, which owns exclusive licensing rights to the product in Chinese mainland, Hong Kong, Macau and Taiwan.
hypoxic induction factor can not only increase the expression of erythrocyte-producing proteins, but also increase the expression of erythrocyte-producing proteins and promote iron absorption and circulation.
"How Cells Perceive and Adapt to Oxygen Supply" won the 2019 Nobel Prize in Physiology or Medicine, and the hypooxygenated factor transcription complex is a key finding.
the world's first approved HIF-PHI-type drug was developed by the company, Rosasta, and was first approved in China.
, GSK's daprodustat, Otsuka Vadadustat and Torii Pharma's enarodustat were approved in Japan in 2020.
is currently more of this target drug layout enterprises, related progress can be seen in the following figure: Source: Pharmaceutical Rubik's Cube NextPharma